Syed Ali obtained his M.S. degree in biochemistry in 1997 from the University of Balochistan, Quetta, Pakistan, and Ph.D. degree in molecular microbiology in August 2005 from the Universiti Sains Malaysia, Pulau Penang, Malaysia. He gained 5-year postdoctoral experience as a Research Fellow at the Morehouse School of Medicine, Atlanta, GA, USA, under the supervision of Dr. Vincent C. Bond. During this time, he also worked at the Yerkes National Primate Center, Emory University, Atlanta, GA, USA, in the Laboratory of Dr. Francois Villinger. Ali secured his current position as a senior university lecturer in September 2010. His research group currently includes 5 Ph.D. students and 1 M.S. student. Major thrust of his research is on developing engineered antibodies (both surface-acting and cell penetrable “transMAbs” ) to be used as novel therapeutics against HIV/AIDS. His team has developed single-chain Fv (scFv) antibodies against HIV-1 p24, an essential structural component and Nef proteins. The central working hypothesis is that engineered therapeutic antibodies against p24 and Nef may be used to prevent these proteins from interaction with their binding partners, thereby controlling spread of HIV. His team has tested these antibodies in HIV-infected T cells (Jurkat) and monocytes (THP1 and U937). A two- to three-log reduction in HIV production was noted in antibody-treated cells compared to control. This research was supported by MOHE’s FRGS Grant (203/CIPPT/6711206), and findings have been submitted to journal Retrovirology for publication. His team is now tooling up to evaluate these antibodies in HIV-1 transgenic mouse model.
Biography Updated on 27 November 2013